A Triumph In Breast Cancer -- And Another Expensive Drug
By:
Forbes Real Time
When there was a bit debate about whether the Food and Drug Administration should withdraw Avastin's accelerated approval in breast cancer, I and others observed that the real complain should be that FDA did not grant accelerated approval of another Roche drug, known as T-DM1.
When there was a bit debate about whether the Food and Drug Administration should withdraw Avastin's accelerated approval in breast cancer, I and others observed that the real complain should be that FDA did not grant accelerated approval of another Roche drug, known as T-DM1.
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here